Our policy team successfully worked with stakeholders in Dublin, London and Brussels, including leading respective trade associations, to ensure modernization of public policies to protect stable access to medicines and the stable flows of exports despite significant changes to import, export and regulatory processes and licensing for medicines passing through the U.K., or with U.K. regulatory elements.